medigraphic.com
Instituto Nacional de Salud Pública

2004, Number 1

<< Back Next >>

salud publica mex 2004; 46 (1)

Usefulness of combining universal oligonucleotides in detecting human papillomavirus in cervical cancer and premalignant lesions

Carrillo A, Mohar A, Meneses A, Frías-Mendivil M, Solorza G, Lizano M

Language: Spanish
References: 57
Page: 7-15
PDF size: 139.46 Kb.


ABSTRACT

Objective. To determine the prevalence of human papillomavirus (HPV) infection at different stages of the natural history of cervical cancer. Also, to optimize its detection by means of different sets of general primers. Material and Methods. A descriptive, cross-sectional study was conducted between January and December 1999. Samples were processed and analyzed at the Instituto Nacional de Cancerología (National Cancerology Institute) in Mexico City. A comparative analysis was performed using Student’s t for continuous values and the chi-squared test for proportions. A contingency analysis was made between biopsy and cervical exudates with the Kappa statistic. HPV detection was done by PCR with general primers which recognize different regions of the L1 gene (MY09/11; GP5/6; L1C1/2) and with HPV16- and HPV18- specific primers, as well as direct sequencing of PCR products. Results. In total, 154 samples were analyzed: 65 (42.2%) of them showed normal cytology; 45 (29.2%) high and low grade lesions; and 44 (28.6%) invasive cervical cancer. HPV was detected in 95.5% of invasive cervical cancers, in 91.6% of high grade lesions, in 66.7% of low grade lesions, and in 23.1% of normal smears, by PCR with at least one set of oligonucleotide primers. HPV detection was more efficient in biopsy specimens than in cervical scrapes. The total percentage of HPV detection using only one set of universal oligonucleotides (37.6%)increased to 60.4% when the other two sets of universal oligonucleotides were used. Conclusions. The frequency of high risk HPV is high even in women with reported normal cytology. HPV detection improves when different sets of general primers directed to the L1 region are used. HPV DNA screening in cervical scrapes may be a good alternative HPV diagnostic tool when the samples are appropriately taken.


REFERENCES

  1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.

  2. Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.

  3. Kuri MP, Méndez VR, De la Garza-Salazar J, Mohar BA, Angeles AA, Chávez ML et al, comp. Compendio del registro histopatológico de neoplasias en México. México, DF. Dirección General de Epidemiología, Secretaría de Salud 1997:41-47.

  4. Mohar A, Frías M, Súchil L, Macías-Martínez C, Tapia-Conyer R. Epidemiología del cáncer cervicouterino en México. Ann Oncol 1998;7:S222-S226.

  5. Mohar A, Frías M. Epidemiology of cervical cancer. Cancer Invest 2000; 18: 584-590.

  6. Muñoz N, Bosch X, De Sanjosé S, Tafur I, Izarzugaza I, Gili M et al. Risk factor for cervical intraepithelial neoplasia grade III/ carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:423-431.

  7. Reeves WC, Brinton LA, García M, Brenes NN, Herrero R, Gaitán E et al. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med 1989;320:1437-1441 .

  8. Muñoz N, Bosch FX, De Sanjosé S, Tafur L, Izarzugaza I, Gili M et al. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-749.

  9. Zur Hausen H. Papillomavirus causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698.

  10. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.

  11. Walboomers J, Jacobs M, Manos MM, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

  12. Ordóñez R, Mendoza L, Reynoso R, Solorza G, Ramírez-Gaytán JL, Meneses A et al. Papilomavirus humano en pacientes con cáncer cervicouterino en el Instituto Nacional de Cancerología. Rev Inst Nal Cancerol 1993;39:1809-1813.

  13. Mendoza-Alcantar L, Lara-Ortiz M, Reynoso-Pablos R, Ramírez-Gaytán JL. Detección del papilomavirus humano en ADN de tejido normal y lesiones premalignas del cérvix por hibridación molecular. Rev Inst Nal Cancerol 1994;40:8-13.

  14. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro C, Chimera J et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-477.

  15. Schiffman M. Validation of VPH hybridization assays: Correlation of filter in situ, Dot blot and PCR with Southern blot. En: Muñoz N, Bosh FX, Shah KV, Meheus A, Ed. The Epidemiology of cervical cancer and human papillomavirus. Lyon: IARC Scientific Publication, 1992;119:169-179.

  16. Guerrero E, Daniel RW, Bosch FX, Castellsagué X, Muñoz N, Gili M et al. Comparison of Virapap, southern hybridization and polymerase chain reaction methods for human papillomavirus identification in a epidemiological investigation of cervical cancer. J Clin Microbiol 1992;30:2951-2959.

  17. Torroella M, Morsberger S, Carrillo A, Mohar A, Meneses A, Ibarra M et al. HPV prevalence among Mexican women with neoplastic and normal cervixes. Gynecol Oncol 1998;70:115-120.

  18. Lazcano-Ponce E, Moss S, Alonso de Ruiz P, Salmerón CJ, Hernández AM. Cervical cancer screening in developing countries: Why is it ineffective? The case of Mexico. Arch Med Res 1999;30:240-250.

  19. Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris DG et al. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV study. Salud Publica Mex 2002;44:335-344.

  20. International Federation of Gynecology and Obstetrics. Staging announcement: FIGO staging of gynecologic cancers: Cervical and vulva. Int J Gynecol Cancer 1995;5:319.

  21. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: A laboratory manual. 2a. edición.Nueva York (NY): Cold Spring Harbor, 1989;vol.2:9-16.

  22. Resnick R, Cornelissen M, Wright D, Eichnigen GH, Fox HS, Schegget J et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990;82:1477-1484.

  23. Van den Brule A, Meijer CJL, Bakels V, Kenemans P, Walboomers JM. Rapid detection of human papillomavirus in cervical scrapes by combined general primer mediated and type specific polymerase chain reaction. J Clin Microbiol 1990;28:2739-2743.

  24. Snijders P, Van den Brule A, Schrijnemaker H, Snow G, Meijer Ch, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990;71:173-181.

  25. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991;82:524-531.

  26. Berumen J, Casas L, Segura E, Amescua JL, García-Carrancá A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int J Cancer 1994;56:640-645.

  27. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V et al. Evolution of human papillomavirus type 18: An ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993;63:6424-6431.

  28. Sanger F, Nicklen S, Coulson A. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-5467.

  29. Zar J. Biostatistical analysis. 2a. edición. Londres:Prentice-Hall, 1984:40-49.

  30. Kelsey J, Thompson D, Evans A. Methods in observational epidemiology. Oxford: Oxford University Press, 1986:285-308.

  31. Muñoz N, Bosch X, De San José S, Herrero R, Castellsagué X, Shah K et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.

  32. Mohar A, Frías M, Suchil L, Mora-Macías T, De la Garza J. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Publica Mex 1997;39: 253-258.

  33. González-Garay M, Barrera-Saldaña H, Avilés L, Alvarez-Salas L, Gariglio P. Prevalence in two Mexican cities of human papillomavirus DNA sequences in cervical cancer. Rev Invest Clin 1992;44:491-499.

  34. Hernández-Avila M, Lazcano-Ponce E, Berumen J, Cruz-Valdés A, Alonso de Ruiz P, Gónzalez-Lira G et al. Human papillomavirus 16-18 infection and cervical cancer in Mexico: A case-control study. Arch Med Res 1997;28:265-271.

  35. Zamora PA, Terrés SA. Infección por virus del papiloma humano en mujeres y hombres mexicanos identificación por el sistema de captura de híbridos. Rev Mex Patol Clin 1998;45:9-16.

  36. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah K, Alonso P et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-420.

  37. Sarkar FH, Crissman JD. Detection of human papillomavirus DNA sequences by polymerase chain reaction. BioTechniques 1990;9:180-185.

  38. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-214.

  39. Husnjak K, Grce M, Magdic L, Pavelic K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Meth 2000;88:125-134.

  40. Kiviat N, Koutsky L, Paavonen J, Galloway D, Critchlow C, Beckmann A et al. Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis 1989;159:293-302.

  41. Melkert P, Hopman E, Van den Brule A, Risse E, Van Diest P, Bleker O et al. Prevalence of HPV in cyto-morphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-923.

  42. Hildesheim A, Schiffman M, Gravitt P, Glass AG, Greer CE, Zhang T et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-240.

  43. Berumen J, Miranda E, Zafra G, Casas L, Segura E, Ordóñez R. Epidemiología molecular de cánceres de alta incidencia en México. Gac Med Mex 1997;133:35-41.

  44. Schiffman M, Bauer H, Hoover R, Glass AG, Cadell DM, Rush BB et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-964.

  45. Remmink A, Walboomers J, Helmerhorst TJM, Voorhorst FJ, Rozendaal I, Risse EKJ et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306-311.

  46. Nobbenhuis M, Walboomers J, Helmerhorst T, Rozendaal L, Remmink J, Risse E et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999;354:20-25.

  47. Herrero R, Hildesheim A, Bratti C, Sherman M, Hutchinson M, Morales J et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474.

  48. Ho G, Bierman R, Beardsley L, Chang Ch, Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.

  49. Lörincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-229.

  50. Muñoz N, Bosch FX, De Sanjosé S, Viladiu P, Tormo J, Moreo P et al. El virus del papiloma humano en la etiología del cáncer cervicouterino. Bol Oficina Sanit Panam 1993;115:301-308.

  51. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer C, Walboomers J. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-119.

  52. Peyton CL, Schiffman M, Lörincz A, Hunt WC, Mielzynska I, Bratti C et al. Comparison of PCR and Hibrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248-3254.

  53. Lizano M, Berumen J, Guido MC, Casas L, García-Carrancá A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 1997;89:1227-1231.

  54. Wheeler Cosette. Preventive vaccines for cervical cancer. Salud Publica Mex 1997;39:283-287.

  55. Berumen J, Villegas N. Vacunas terapéuticas recombinantes contra el cáncer del cuello uterino. Salud Publica Mex 1997;39:288-297.

  56. Gariglio P, Benítez-Bribiesca L, Berumen J, Alcocer JM, Tamez R, Madrid V. Therapeutic uterine-cervix cancer vaccines in humans. Arch Med Res 1998;29:279-284.

  57. Cornelison T. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Curr Opin Oncol 2000;12:466-473.




2020     |     www.medigraphic.com